Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 16, 2022 (5 years ago)

Olanzapine Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGmp Deviations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Olanzapine Tablets, USP 10 mg, 30-count bottles, Rx only, Manufactured for: Macleods Pharma USA , Inc. Plainsboro, NJ 08536, Manufactured by: Macleods Pharmaceuticals Ltd., Baddi, HImachal Pradesh, India, NDC 33342-070-07.

Affected NDC 33342-0070-07

Compare with the code on your package — it is the most precise check available.

Drug: Olanzapine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Olanzapine
NDC 33342-0070
10 mg/1 Tablet, Film Coated
Oral
Macleods Pharmaceuticals Limited Rx
Recalling firm
Macleods Pharma Usa Inc
NDC code
33342-070-07
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0639-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Olanzapine recalls

See all
Class III · Low risk

Olanzapine Tablets

Failed Impurities/Degradation Specifications:Organic and unspecified impurities above specification.

Ongoing Impurity / degradation Macleods Pharmaceuticals Limited NDC 33342-068-07 D-0867-2026
Class II · Moderate risk

Zyprexa Intramuscular

cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.

Terminated cGMP deviation Eli Lilly & Company NDC 0002-7597-01 D-0720-2021

Other recalls by Macleods Pharma Usa Inc

All 2022 recalls
Class III · Low risk

Levofloxacin Tablets

Mismatching of the embossing on the tablets (T7) with the embossing mentioned in the package insert (ML63) in the distributed bottles.

Terminated Labeling / mix-up Macleods Pharma USA, INC NDC 33342-022-08 D-0162-2023
Class II · Moderate risk

Eszopiclone Tablets

Shortfill: customer complaints of one to three tablets were reported missing from 30 count bottles.

Terminated Failed specification Macleods Pharma Usa Inc NDC 33342-299-07 D-1174-2022